Hot Features
Premium
Level up your trading with our powerful tools and real-time insights all in one place.
Period:
Draw Mode:
| Volume | 101,024 |
|
|||||
| News | (1) | ||||||
| Day High | 3.90 | Low High |
|||||
| Day Low | 3.73 | ||||||
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Mural Oncology PLC | MURA | NASDAQ | Common Stock |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.01 | 0.26% | 3.83 | 16:28:45 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 3.85 | 3.73 | 3.90 | 3.83 | 3.82 |
| Trades | Shares Traded | VWAP | Financial Volume | Average Volume | 52 Week Range |
|---|---|---|---|---|---|
| 1,669 | 101,024 | US$ 3.80 | US$ 384,221 | - | 3.23 - 17.00 |
| Last Trade | Type | Quantity | Price | Currency |
|---|---|---|---|---|
| 15:17:44 | 30 | US$ 3.88 | USD |
Mural Oncology PLC Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| US$ 64.81M | - | - | - | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Mural Oncology News
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical MURA Price Data
| Period † | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.54 | 3.91 | 3.48 | 3.72 | 110,177 | 0.29 | 8.19% |
| 1 Month | 4.74 | 4.74 | 3.44 | 3.93 | 201,672 | -0.91 | -19.20% |
| 3 Months | 4.26 | 5.623 | 3.44 | 4.62 | 237,550 | -0.43 | -10.09% |
| 6 Months | 16.69 | 17.00 | 3.23 | 4.35 | 475,132 | -12.86 | -77.05% |
| 1 Year | 16.69 | 17.00 | 3.23 | 4.35 | 475,132 | -12.86 | -77.05% |
| 3 Years | 16.69 | 17.00 | 3.23 | 4.35 | 475,132 | -12.86 | -77.05% |
| 5 Years | 16.69 | 17.00 | 3.23 | 4.35 | 475,132 | -12.86 | -77.05% |
Mural Oncology Description
| Mural Oncology¿s pipeline is built to address difficult-to-treat tumor types where checkpoint inhibitors are not effective. The Company¿s lead product candidate, nemvaleukin alfa (nemvaleukin), is an investigational, engineered interleukin-2 (IL-2) cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 (rhIL-2), while mitigating the hallmark toxicities of native IL-2 in difficult-to-treat cancers with high unmet need. Nemvaleukin is currently in two potentially registrational studies: one for the treatment of mucosal melanoma as a monotherapy and one for the treatment of platinum-resistant ovarian cancer (PROC) in combination with pembrolizumab. |
